IGM Biosciences (IGMS) Short Interest Ratio & Short Volume $6.90 -0.15 (-2.13%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IGM Biosciences Short Interest DataIGM Biosciences (IGMS) has a short interest of 2.70 million shares, representing 15.41% of the float (the number of shares available for trading by the public). This marks a -4.93% decrease in short interest from the previous month. The short interest ratio (days to cover) is 8.7, indicating that it would take 8.7 days of the average trading volume of 301,638 shares to cover all short positions.Current Short Interest2,700,000 sharesPrevious Short Interest2,840,000 sharesChange Vs. Previous Month-4.93%Dollar Volume Sold Short$27.11 millionShort Interest Ratio8.7 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares59,464,000 sharesFloat Size17,520,000 sharesShort Percent of Float15.41%Today's Trading Volume434,862 sharesAverage Trading Volume301,638 sharesToday's Volume Vs. Average144% Short Selling IGM Biosciences? Sign up to receive the latest short interest report for IGM Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIGMS Short Interest Over TimeIGMS Days to Cover Over TimeIGMS Percentage of Float Shorted Over Time Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. IGM Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/20242,700,000 shares $27.11 million -4.9%15.4%8.7 $10.04 11/15/20242,840,000 shares $26.89 million -15.7%16.2%9.3 $9.47 10/31/20243,370,000 shares $57.76 million -8.4%16.3%11.6 $17.14 10/15/20243,680,000 shares $56.78 million -8.5%17.8%12.1 $15.43 9/30/20244,020,000 shares $66.49 million -23.9%19.3%11.4 $16.54 9/15/20245,280,000 shares $64.94 million -4.7%25.3%16.7 $12.30 Get the Latest News and Ratings for IGMS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter. 8/31/20245,540,000 shares $56.45 million -4.2%26.7%20 $10.19 8/15/20245,780,000 shares $53.58 million +2.5%27.8%16.4 $9.27 7/31/20245,640,000 shares $62.94 million -1.1%27.2%15.6 $11.16 7/15/20245,700,000 shares $59.11 million +9.2%27.2%15.2 $10.37 6/30/20245,220,000 shares $35.86 million +0.8%24.9%16.1 $6.87 6/15/20245,180,000 shares $37.71 million +0.8%24.7%16.1 $7.28 5/31/20245,140,000 shares $42.82 million -2.7%24.1%15.8 $8.33 5/15/20245,280,000 shares $50.11 million -15.4%24.8%17.2 $9.49 4/30/20246,240,000 shares $60.09 million +18.9%29.9%21.6 $9.63 4/15/20245,250,000 shares $49.40 million +0.6%25.0%19.4 $9.41 3/31/20245,220,000 shares $50.37 million +9.7%25.1%18.5 $9.65 3/15/20244,760,000 shares $50.65 million +5.5%22.9%16.4 $10.64 2/29/20244,510,000 shares $56.96 million -1.3%21.4%14.5 $12.63 2/15/20244,570,000 shares $70.38 million -2.6%21.9%14 $15.40 1/31/20244,690,000 shares $49.34 million -4.1%22.5%15.3 $10.52 1/15/20244,890,000 shares $53.50 million +4.7%23.5%14.2 $10.94 12/31/20234,670,000 shares $38.81 million +7.9%22.4%13.2 $8.31 12/15/20234,330,000 shares $28.58 million +5.4%20.9%12.5 $6.60 11/30/20234,110,000 shares $27.70 million -1.0%19.8%12.6 $6.74 11/15/20234,150,000 shares $24.49 million -17.0%20.0%13.9 $5.90 10/31/20235,000,000 shares $19.70 million -6.2%24.1%17.2 $3.94 10/15/20235,330,000 shares $23.51 million +1.5%25.7%20.6 $4.41 9/30/20235,250,000 shares $43.84 million -6.6%25.3%22.1 $8.35 9/15/20235,620,000 shares $41.36 million -0.4%27.1%21.3 $7.36 8/31/20235,640,000 shares $40.33 million +2.9%28.2%19 $7.15 8/15/20235,480,000 shares $42.74 million +12.3%27.4%17.1 $7.80 7/31/20234,880,000 shares $51.92 million -1.6%24.3%15.2 $10.64 7/15/20234,960,000 shares $49.60 million +2.3%26.1%15.8 $10.00 6/30/20234,850,000 shares $44.77 million +8.3%26.3%14.3 $9.23 6/15/20234,480,000 shares $45.07 million +2.5%24.2%13.4 $10.06 5/31/20234,370,000 shares $52.66 million +5.1%24.8%16.3 $12.05 5/15/20234,160,000 shares $57.32 million +2.5%23.7%18 $13.78 4/30/20234,060,000 shares $43.97 million +3.3%23.3%17.9 $10.83 4/15/20233,930,000 shares $43.66 million +7.4%22.8%18.2 $11.11Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 3/31/20233,660,000 shares $50.29 million -0.5%21.2%16.1 $13.74 3/15/20233,680,000 shares $69.59 million +3.7%21.1%20.5 $18.91 2/28/20233,550,000 shares $74.62 million -2.2%20.3%18.1 $21.02 2/15/20233,630,000 shares $87.05 million -4.5%20.8%17.4 $23.98 1/31/20233,800,000 shares $86.37 million +5.0%21.8%16.2 $22.73 1/15/20233,620,000 shares $91.69 million +4.3%20.9%15.1 $25.33 12/30/20223,470,000 shares $59.02 million -4.7%20.0%16 $17.01 12/15/20223,640,000 shares $67.34 million +12.7%20.9%15.8 $18.50 11/30/20223,230,000 shares $71.09 million -9.3%18.7%14.9 $22.01 11/15/20223,560,000 shares $92.63 million +5.6%20.6%16.2 $26.02 10/31/20223,370,000 shares $67.40 million -2.3%19.5%17.4 $20.00 10/15/20223,450,000 shares $71.35 million +3.6%19.9%18 $20.68 9/30/20223,330,000 shares $75.72 million +3.4%19.2%17 $22.74 9/15/20223,220,000 shares $71.55 million -3.9%18.6%16.2 $22.22 8/31/20223,350,000 shares $65.02 million +3.1%20.1%15.3 $19.41 8/15/20223,250,000 shares $87.78 million -2.1%19.5%13.7 $27.01 7/31/20223,320,000 shares $53.49 million +1.2%21.1%12.2 $16.11 7/15/20223,280,000 shares $61.01 million +6.2%20.8%11.1 $18.60 6/30/20223,090,000 shares $55.71 million +4.4%19.6%9.1 $18.03 6/15/20222,960,000 shares $41.88 million -10.0%18.8%2.5 $14.15 5/31/20223,290,000 shares $55.21 million -6.3%20.9%2.8 $16.78 5/15/20223,510,000 shares $51.11 million -10.7%22.3%3 $14.56 4/30/20223,930,000 shares $65.79 million -9.0%27.0%3.4 $16.74 4/15/20224,320,000 shares $87.48 million -1.6%29.6%3.7 $20.25 3/31/20224,390,000 shares $117.34 million -3.1%N/A3.8 $26.73 3/15/20224,530,000 shares $60.79 million -1.7%30.8%14.3 $13.42 2/28/20224,610,000 shares $76.89 million -1.5%31.3%13.5 $16.68 2/15/20224,680,000 shares $80.96 million +2.2%31.7%13.8 $17.30 1/31/20224,580,000 shares $81.07 million +7.0%31.1%13.8 $17.70 1/15/20224,280,000 shares $93.65 million +3.6%N/A0 $21.88 12/31/20214,130,000 shares $121.13 million +14.1%28.0%15.4 $29.33 12/15/20213,620,000 shares $102.63 million -0.8%24.5%14.3 $28.35 11/30/20213,650,000 shares $182.21 million +1.1%24.8%20.9 $49.92 11/15/20213,610,000 shares $216.56 million +7.8%24.4%21.7 $59.99 10/29/20213,350,000 shares $157.18 million +2.8%22.9%21.6 $46.92 10/15/20213,260,000 shares $192.05 million +3.2%22.6%23.7 $58.91 9/30/20213,160,000 shares $207.80 million -1.3%21.9%24.1 $65.76 9/15/20213,200,000 shares $218.75 million -3.6%22.2%24.7 $68.36 8/31/20213,320,000 shares $236.42 million -0.3%23.1%24.2 $71.21 8/13/20213,330,000 shares $251.55 million +12.9%23.1%23 $75.54 7/30/20212,950,000 shares $200.63 million +1.0%20.6%19.6 $68.01 7/15/20212,920,000 shares $238.80 million -1.0%20.4%20.2 $81.78 6/30/20212,950,000 shares $245.44 million -3.6%20.6%18.4 $83.20 6/15/20213,060,000 shares $272.10 million +6.3%21.3%17.1 $88.92 5/28/20212,880,000 shares $214.99 million -3.4%20.1%14.7 $74.65 5/14/20212,980,000 shares $194.92 million -0.7%20.8%15.1 $65.41 4/30/20213,000,000 shares $215.37 million -0.3%21.0%15 $71.79 4/15/20213,010,000 shares $192.43 million -15.5%21.1%15.3 $63.93 3/31/20213,560,000 shares $267.21 million +47.7%24.9%18.2 $75.06 3/15/20212,410,000 shares $211.67 million +12.6%16.9%11.5 $87.83Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 2/26/20212,140,000 shares $179.65 million +10.3%15.0%7.4 $83.95 2/12/20211,940,000 shares $212.14 million -13.8%13.6%6.7 $109.35 1/29/20212,250,000 shares $214.52 million -8.5%15.8%7.6 $95.34 1/15/20212,460,000 shares $232.40 million -3.9%17.3%7.9 $94.47 12/31/20202,560,000 shares $233.42 million +18.0%18.0%8 $91.18 12/15/20202,170,000 shares $189.74 million -6.1%15.3%6.9 $87.44 11/30/20202,310,000 shares $156.34 million +5.5%17.6%7.7 $67.68 11/15/20202,190,000 shares $117.10 million +12.3%16.7%10.2 $53.47 10/30/20201,950,000 shares $107.13 million +29.1%14.9%9.8 $54.94 10/15/20201,510,000 shares $118.23 million -3.8%11.5%9.1 $78.30 9/30/20201,570,000 shares $115.88 million +1.3%12.0%11.2 $73.81 9/15/20201,550,000 shares $103.21 million +14.0%11.8%11.6 $66.59 8/31/20201,360,000 shares $58.48 million +3.0%10.4%12.6 $43.00 8/14/20201,320,000 shares $68.53 million +1.5%10.1%13.5 $51.92 7/31/20201,300,000 shares $65.34 million +20.4%10.0%13.2 $50.26 7/15/20201,080,000 shares $67.69 million +4.9%8.3%11.7 $62.68 6/30/20201,030,000 shares $69.98 million +38.4%7.9%10.8 $67.94 6/15/2020744,200 shares $46.54 million +2.3%5.7%8.3 $62.54 5/29/2020727,400 shares $47.27 million +9.3%5.6%7.9 $64.99 5/15/2020665,300 shares $38.64 million +1.1%5.1%6.5 $58.08 4/30/2020658,300 shares $36.06 million +5.7%5.1%5.6 $54.77 4/15/2020622,900 shares $34.88 million +11.5%4.8%5 $56.00 3/31/2020558,500 shares $31.56 million +24.7%4.3%4 $56.50 3/13/2020448,000 shares $29.04 million -0.8%3.5%2.8 $64.83 2/28/2020451,500 shares $23.32 million +1.1%3.5%2.7 $51.64 2/14/2020446,700 shares $22.52 million -22.0%3.5%2.8 $50.41 1/31/2020572,300 shares $30.62 million -14.7%4.5%3.7 $53.50 1/15/2020670,900 shares $28.82 million +45.6%5.3%4.4 $42.96 12/31/2019460,800 shares $18.35 million No Change3.7%3.4 $39.83 IGMS Short Interest - Frequently Asked Questions What is IGM Biosciences' current short interest? Short interest is the volume of IGM Biosciences shares that have been sold short but have not yet been covered or closed out. As of November 30th, investors have sold 2,700,000 shares of IGMS short. 15.41% of IGM Biosciences' shares are currently sold short. Learn More on IGM Biosciences' current short interest. What is a good short interest ratio for IGM Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IGMS shares currently have a short interest ratio of 9.0. Learn More on IGM Biosciences's short interest ratio. What is a good short interest percentage for IGM Biosciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.41% of IGM Biosciences' floating shares are currently sold short. Is IGM Biosciences' short interest increasing or decreasing? IGM Biosciences saw a decrease in short interest in the month of November. As of November 30th, there was short interest totaling 2,700,000 shares, a decrease of 4.9% from the previous total of 2,840,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is IGM Biosciences' float size? IGM Biosciences currently has issued a total of 59,464,000 shares. Some of IGM Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. IGM Biosciences currently has a public float of 17,520,000 shares. How does IGM Biosciences' short interest compare to its competitors? 15.41% of IGM Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to IGM Biosciences: Evotec SE (0.14%), Arcutis Biotherapeutics, Inc. (20.10%), Nurix Therapeutics, Inc. (13.20%), Arcus Biosciences, Inc. (16.69%), Kiniksa Pharmaceuticals, Ltd. (5.57%), Immunocore Holdings plc (14.78%), Ocular Therapeutix, Inc. (6.78%), Mesoblast Limited (1.24%), Travere Therapeutics, Inc. (9.70%), Intellia Therapeutics, Inc. (18.57%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short IGM Biosciences stock? Short selling IGMS is an investing strategy that aims to generate trading profit from IGM Biosciences as its price is falling. IGMS shares are trading down $0.15 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against IGM Biosciences? A short squeeze for IGM Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IGMS, which in turn drives the price of the stock up even further. How often is IGM Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IGMS, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies EVO Short Squeeze ARQT Short Squeeze NRIX Short Squeeze RCUS Short Squeeze KNSA Short Squeeze IMCR Short Squeeze OCUL Short Squeeze MESO Short Squeeze TVTX Short Squeeze NTLA Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IGMS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
